ORIGINAL COMMUNICATION

Thrombolysis in stroke patients with elevated inflammatory markers

Valerian L. Altersberger1 · Lukas S. Enz1 · Gerli Sibolt2 · Christian Hametner3 · Stefania Nannoni4 · Mirjam R. Heldner5 · Jeffrey Stolp5 · Dejana J. Rovanovic7 · Andrea Zini8 · Alessandro Pezzini9 · Susanne Wegener10 · Carlo W. Cereda11 · George Ntaios12 · Silja Räty · Christoph Gumbinger3 · Miriam Heys3 · Alexandros A. Polymeris1 · Annuelle Zietz1 · Anna Schaufelbuehli1 · Davide Strambio4 · Giovanna Padlina2 · Nedelina Slavova13 · Marjaana Taininen2 · Kati Valkonen2 · Twan J. van Velzen6 · Guido Bigliardi6 · Predrag Stanarcevic7 · Mauro Magoni15 · Andreas Luft10 · Yannick Bejot16 · Laura Vandelli14 · Visnja Padjen7 · Paul J. Nederkoorn6 · Marcel Arnold5 · Patrik Michel4 · Peter A. Ringleb3 · Sami Curtze2 · Stefan T. Engelter1,17 · Henrik Gensicke1,17 · for the Thrombolysis in Stroke Patients (TRISP) collaborators

Received: 9 January 2022 / Revised: 1 May 2022 / Accepted: 3 May 2022 / Published online: 27 May 2022
© The Author(s) 2022

Abstract
Objective To investigate the prognostic value of white blood cell count (WBC) on functional outcome, mortality and bleeding risk in stroke patients treated with intravenous thrombolysis (IVT).

Methods In this prospective multicenter study from the TRISP registry, we assessed the association between WBC on admission and 3-month poor outcome (modified Rankin Scale 3–6), mortality and occurrence of symptomatic intracranial hemorrhage (sICH; ECASS-II-criteria) in IVT-treated stroke patients. WBC was used as continuous and categorical variable distinguishing leukocytosis (WBC > 10 × 10⁹/l) and leukopenia (WBC < 4 × 10⁹/l). We calculated unadjusted/ adjusted odds ratios with 95% confidence intervals (OR [95% CI]) with logistic regression models. In a subgroup, we analyzed the association of combined leukocytosis and elevated C-reactive protein (CRP > 10 mg/l) on outcomes.

Results Of 10,813 IVT-treated patients, 2527 had leukocytosis, 112 leukopenia and 8174 normal WBC. Increasing WBC (by 1 × 10⁹/l) predicted poor outcome (ORadjusted 1.04[1.02–1.06]) but not mortality and sICH. Leukocytosis was independently associated with poor outcome (ORadjusted 1.48[1.29–1.69]) and mortality (ORadjusted 1.60[1.35–1.89]) but not with sICH (ORadjusted 1.17[0.94–1.45]). Leukopenia did not predict any outcome. In a subgroup, combined leukocytosis and elevated CRP had the strongest association with poor outcome (ORadjusted 2.26[1.76–2.91]) and mortality (ORadjusted 2.43[1.86–3.16]) when compared to combined normal WBC and CRP.

Conclusion In IVT-treated patients, leukocytosis independently predicted poor functional outcome and death. Bleeding complications after IVT were not independently associated with leukocytosis.

Keywords Stroke · Thrombolysis · White blood cell count · CRP · Inflammation

Introduction

Systemic inflammation response is typical in patients with acute ischemic stroke (AIS) and can be caused by comorbidities (e.g., infections, malignancies or rheumatologic disorders) as well as local inflammatory processes of stroke-induced brain injury [1–3]. Inflammation enhances microvascular dysfunction and edema expansion, which ultimately can worsen the clinical outcome [4]. In clinical routine, white blood cell count (WBC) and C-reactive protein (CRP) are frequently used laboratory parameters to evaluate systemic inflammatory response [5].

In previous studies, leukocytosis (= elevated WBC) and elevated CRP were associated with more severe strokes and larger infarct volume in the general stroke population [6–9]. However, the effect of WBC and CRP on outcomes in acute stroke patients treated with IVT is contradictory. In one study, leukocytosis on admission was independently associated with poor functional outcome and occurrence of
symptomatic intracranial hemorrhage (sICH) [10]. In contrast, another study did not find any association between baseline WBC and functional outcome, mortality or sICH [11]. Elevated CRP on admission was associated with poor functional outcome in one study [10] but not in another [6]. To the best of our knowledge, the combined effect of leukocytosis and elevated CRP on outcomes in IVT-treated stroke patients has not been investigated. In addition, the association of leukopenia with outcomes in this patient cohort is unknown.

With these considerations in mind, we conducted this multicenter cohort study to investigate, first, the association of WBC with outcomes in acute ischemic stroke patients treated with IVT. Second, we evaluated the prognostic importance of leukocytosis if combined with elevated CRP.

**Methods**

For this cohort study, we used prospectively collected data from the international, multicenter ThRombolysis in Ischemic Stroke Patients (TRISP) collaboration, which has been described previously [12]. Thirteen TRISP centers participated in this study (Table Supplementary-1). A complete list of all TRISP centers is presented in the appendix (Appendix Table 5). Data collection was done locally in each stroke center using a standardized form with predefined variables [13]. Data of the local registries were pooled and analyzed in an anonymized way at the stroke center Basel. Variables of interest for the present study were age, sex, National Institutes of Health Stroke Scale (NIHSS) score [14], blood pressure prior to IVT treatment, onset-to-treatment time, creatinine and glucose levels, WBC and CRP in blood samples on admission, vascular risk factors according to predefined criteria [15] and prior treatment with antithrombotic agents (antiplatelet agents or anticoagulants). Outcome parameters were mortality and the modified Rankin Scale (mRS) score at 3 months assessed by either outpatient visits or telephone calls with patients and/or relatives. Poor functional outcome was defined as an mRS score of 3–6. As safety outcome, we defined the occurrence of sICH using the ECASS-II-criteria [16]. Intracranial hemorrhage was monitored by follow-up CT or MRI as described in prior research [17].

Included data were collected between June 1995 and December 2018. We excluded patients with missing data on (i) WBC on admission or (ii) 3-month outcome.

**Statistical analyses**

Statistical analyses were performed with SPSS Statistics version 25 (IBM) and with R (R Core Team (2021). *R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. URL https://www.R-project.org/) and RStudio (RStudio Team (2022). *RStudio: Integrated Development Environment for R. RStudio, PBC, Boston, MA URL http://www.rstudio.com/).*

We investigated the associations between WBC and outcomes using WBC as a (i) continuous variable and as a (ii) categorical variable distinguishing leukocytosis (WBC > 10 × 10⁹/l) and leukopenia (WBC < 4 × 10⁹/l) according to current hematological definitions [18, 19]. Normal WBC (4–10 × 10⁹/l) served as reference group.

Continuous data were summarized as median and interquartile range (IQR). We used chi² test and Fisher’s exact test for categorical variables where appropriate and the Mann–Whitney U test for continuous variables. The association between WBC (± CRP) with each outcome was estimated by calculating odds ratios (OR) with 95% confidence intervals (95% CI), using binary logistic regression models. All baseline variables with Bonferroni adjusted \( p \) < 0.1 in univariable analyses were included in the multivariable analyses using stepwise regression with backward elimination based on the likelihood ratio test. To avoid overfitting, the maximum number of potential confounders in the final model was restricted to one-tenth of the number of outcome events, while maintaining age and NIHSS on admission as mandatory covariates in each model. Collinearity was checked in the final models by calculating the maximum generalized variance inflation factor using the car package in R, assuming a value below 5 indicating no relevant collinearity [20].

**Subgroup analyses**

In ten of the 13 participating centers, data on CRP on admission were available. We excluded patients from centers with missing data on CRP from the subgroup analysis (Fig. 1). In this subgroup, we assessed the association of combined leukocytosis and elevated CRP (normal range CRP < 10 mg/l [21]) on sICH, poor outcome and mortality. Patients with normal WBC and CRP served as reference group. In addition, we investigated the association between CRP and outcomes using CRP as a continuous variable.

Post hoc, we examined the association between leukocytosis and poor outcome and mortality using multivariable logistic regression models in patients admitted during three different time periods: 1995–2008, 2009–2015 and 2015–2018.

**Standard protocol approvals, registrations, and patient consents**

The study was approved by the ethics committee in Basel, Switzerland and written informed consent was waived. The requirement for additional local ethical approval differed between participating centers and was obtained if required.
Data availability statement

Anonymized data will be shared by request from any qualified investigator.

Results

Data were eligible for analysis in 10,813 (93.3%) of the 11,585 IVT-treated patients. Reasons for exclusion were missing data on WBC ($n = 415; 3.6\%$) or 3-month mRS ($n = 357; 3.1\%$) (Fig. 1).

Among eligible patients, 8174 (75.6\%) had normal WBC, 2527 (23.4\%) leukocytosis and 112 (1.0\%) leukopenia.

Leukocytosis versus normal WBC

Baseline characteristics are presented in Table 1. Patients with leukocytosis were younger, more often active smokers, had more severe strokes on admission, longer-onset-to-treatment times and more often diabetes mellitus, prior ischemic stroke and pre-stroke disability compared to patients with normal WBC. Furthermore, patients with leukocytosis had more often poor functional outcome (49.7\% vs 38.9\%) and died more often (18.2\% vs 11.8\%) within the first 3 months and had a higher rate of sICH (5.1\% vs 4.1\%) (Table 1; Fig. 2).

In unadjusted logistic regression analyses, leukocytosis increased the odds of poor functional outcome ($OR_{\text{unadjusted}} 1.56, 95\% \text{ CI} 1.42–1.70$), mortality ($OR_{\text{unadjusted}} 1.66, 95\% \text{ CI} 1.47–1.88$) and sICH ($OR_{\text{unadjusted}} 1.26, 95\% \text{ CI} 1.02–1.55$) (Table 2). After adjusting for potential confounders, the association of poor outcome ($OR_{\text{adjusted}} 1.48, 95\% \text{ CI} 1.29–1.89$) and mortality ($OR_{\text{adjusted}} 1.51, 95\% \text{ CI} 1.22–1.86$) with leukocytosis remained (Table 3). Using the same adjusted model, the association between leukocytosis and poor outcome and mortality remained stable over the long time period of data collection: (i) 1995–2008: poor outcome $OR_{\text{adjusted}} 1.44, 95\% \text{ CI} 1.10–1.89$; mortality $OR_{\text{adjusted}} 1.57, 95\% \text{ CI} 1.12–2.19$; (ii) 2009–2015: poor outcome $OR_{\text{adjusted}} 1.43, 95\% \text{ CI} 1.21–1.89$; mortality $OR_{\text{adjusted}} 1.51, 95\% \text{ CI} 1.22–1.86$; (iii) 2015–2018: poor outcome $OR_{\text{adjusted}} 2.07, 95\% \text{ CI} 1.33–3.21$; mortality $OR_{\text{adjusted}} 2.17, 95\% \text{ CI} 1.35–3.48$ (Table Supplementary-3). Leukocytosis increased the odds for sICH in the unadjusted ($OR_{\text{unadjusted}} 1.26, 95\% \text{ CI} 1.02–1.55$) but not in the adjusted analyses ($OR_{\text{unadjusted}} 1.17, 95\% \text{ CI} 0.94–1.45$) (Tables 2 and 3). The maximum variance inflation factor for this model was 1.19, suggesting no relevant collinearity disturbing the model.
Leukopenia versus normal WBC

Compared to normal WBC, leukopenia (n = 112; 1.04%) did not significantly change the odds for any outcome (poor functional outcome OR\textsubscript{adjusted} 1.05, 95% CI 0.66–1.65; mortality OR\textsubscript{adjusted} 1.32, 95% CI 0.69–2.38; sICH OR\textsubscript{adjusted} 1.02, 95% CI 0.35–2.30) (Table 3).

WBC as a continuous variable

Increasing WBC was associated with poor outcome (increase by 1×10^9/l, OR\textsubscript{unadjusted} 1.07, 95% CI 1.05–1.08) but not with mortality (OR\textsubscript{unadjusted} 1.00, 95% CI 1.00–1.01) and sICH (OR\textsubscript{unadjusted} 1.00, 95% CI 0.99–1.00) (Table 3). After adjusting for potential confounders the association of poor outcome (OR\textsubscript{adjusted} 1.04, 95% CI 1.02–1.06) with WBC
Table 2  Putative predicting variables. Odds ratio (95% confidence interval), adj. p-value1

| Putative predicting variables | sICH | Poor outcome | Mortality |
|------------------------------|------|--------------|-----------|
| Age (each year)              | 1.02 (1.02–1.03), adj. p < 0.001 | 1.05 (1.05–1.05), adj. p < 0.001 | 1.07 (1.06–1.07), adj. p < 0.001 |
| Female sex                   | 0.81 (0.67–0.97), adj. p = 1 | 0.68 (0.63–0.73), adj. p < 0.001 | 0.73 (0.65–0.82), adj. p < 0.001 |
| NIHSS (each point)           | 1.07 (1.06–1.08), adj. p < 0.001 | 1.18 (1.18–1.19), adj. p < 0.001 | 1.15 (1.14–1.16), adj. p < 0.001 |
| Systolic blood pressure (each 10 mmHg) | 1.00 (1.00–1.01), adj. p = 1 | 1.00 (1.00–1.00), adj. p = 0.399 | 1.00 (1.00–1.00), adj. p = 1 |
| Onset-to-IVT time min (each minute) | 1.00 (1.00–1.00), Trend2: +, adj. p = 0.004 | 1.00 (1.00–1.00), Trend2: +, adj. p = 0.197 |
| Creatinine (by 1 umol/l)     | 1.00 (1.00–1.00), Trend2: +, adj. p < 0.001 | 1.00 (1.00–1.00), adj. p < 0.001 | 1.01 (1.00–1.01), adj. p < 0.001 |
| Glucose (each mmol/l)        | 1.07 (1.04–1.10), adj. p < 0.001 | 1.12 (1.10–1.14), adj. p < 0.001 | 1.11 (1.09–1.13), adj. p < 0.001 |
| Independent prior to stroke (pre-mRS 0–2) | 0.68 (0.48–0.99), adj. p = 1 | 0.07 (0.06–0.10), adj. p < 0.001 | 0.22 (0.18–0.26), adj. p < 0.001 |
| Prior antithrombotics        | 1.58 (1.31–1.91), adj. p < 0.001 | 1.58 (1.46–1.71), adj. p < 0.001 | 1.97 (1.75–2.21), adj. p < 0.001 |
| Atrial fibrillation          | 1.54 (1.26–1.87), adj. p < 0.001 | 2.01 (1.84–2.19), adj. p < 0.001 | 2.12 (1.88–2.38), adj. p < 0.001 |
| Hypertension                 | 1.35 (1.10–1.67), adj. p = 0.272 | 1.55 (1.43–1.69), adj. p < 0.001 | 1.53 (1.35–1.74), adj. p < 0.001 |
| Current (or stopped <2y) Smoking | 0.58 (0.43–0.77), adj. p = 0.014 | 0.68 (0.61–0.75), adj. p < 0.001 | 0.49 (0.41–0.58), adj. p < 0.001 |
| Hypercholesterolemia         | 1.06 (0.88–1.28), adj. p = 1 | 0.89 (0.83–0.96), adj. p = 0.208 | 0.91 (0.81–1.02), adj. p = 1 |
| Diabetes mellitus            | 1.36 (1.08–1.68), adj. p = 0.373 | 1.74 (1.58–1.92), adj. p < 0.001 | 1.66 (1.46–1.89), adj. p < 0.001 |
| Coronary artery disease      | 1.39 (1.12–1.72), adj. p = 0.158 | 1.41 (1.28–1.56), adj. p < 0.001 | 1.90 (1.67–2.15), adj. p < 0.001 |
| Prior ischemic stroke        | 1.24 (0.96–1.58), adj. p = 1 | 1.49 (1.34–1.67), adj. p < 0.001 | 1.58 (1.37–1.83), adj. p < 0.001 |
| Leukocytosis (vs normal WBC) | 1.26 (1.02–1.55), adj. p = 1 | 1.56 (1.42–1.70), adj. p < 0.001 | 1.66 (1.47–1.88), adj. p < 0.001 |
| Leukopenia (vs normal WBC)   | 1.00 (0.35–2.23), adj. p = 1 | 0.91 (0.62–1.33), adj. p = 1 | 1.09 (0.62–1.80), adj. p = 1 |
| Increasing WBC (by 1)        | 1.00 (0.99–1.00), adj. p = 1 | 1.07 (1.05–1.08), adj. p < 0.001 | 1.00 (1.00–1.01), adj. p = 1 |

1Whole table adjusted by Bonferroni’s method

2If numerically unclear, trend indicates the direction of association: “+” indicates a positive relation (i.e., mean larger than 1), “–” a negative relation (i.e., mean smaller than 1)

Table 3  Multivariable analysis of outcomes. Odds ratio (95% confidence interval), p-value

| Putative predicting variables | sICH | Poor outcome | Mortality |
|------------------------------|------|--------------|-----------|
| Leukocytosis vs normal WBC   | 1.17 (0.94–1.45)4 p = 0.164 | 1.48 (1.29–1.69)3 p < 0.001 | 1.60 (1.35–1.89)4 p < 0.001 |
| Leukopenia vs normal WBC     | 1.02 (0.35–2.30)2 p = 0.969 | 1.05 (0.66–1.65)2 p = 0.827 | 1.32 (0.35–2.30)2 p = 0.379 |
| Increasing WBC (by 1 × 109/l) | 1.00 (0.98–1.00)3 p = 0.721 | 1.04 (1.02–1.06)3 p < 0.001 | 1.00 (1.00–1.01)3 p = 0.996 |

1Adjusted for: age, NIHSS on admission, glucose on admission, prior antithrombotics

2Adjusted for: age, NIHSS on admission

3Adjusted for: age, gender, NIHSS on admission, glucose on admission, independence prior to stroke, prior ischemic stroke

4Adjusted for: age, NIHSS on admission, creatinine on admission, glucose on admission, independence prior to stroke, prior antithrombotics, coronary artery disease

remained. The maximum variance inflation factor for this model was 1.06, suggesting no relevant collinearity disturbing the model.

**Subgroup of patients with available information on CRP and WBC**

Out of 9651 patients, data on CRP were available in 8055 patients. (Fig. 1). Of those, 622 (7.7%) patients had elevated CRP combined with leukocytosis, whereas WBC and CRP were normal in 5’177 (64.3%) patients. Baseline characteristics of these two groups are presented in Table Supplementary-2. Poor outcome (64.0% vs 36.5%) and mortality (28.5% vs 10.3%) were more frequent in patients with combined leukocytosis and elevated CRP.

Combined leukocytosis and elevated CRP was independently associated with poor functional outcome (ORunadjusted 3.07, 95% CI 2.53–3.73 and ORadjusted 2.26.
Elevated CRP and leukocytosis (vs normal WBC and normal CRP) but not with sICH (ORadjusted 1.00, 95% CI 0.99–1.01) and mortality (ORadjusted 1.01, 95% CI 1.01–1.02) but not with sICH compared to normal WBC and CRP (Table 4).

In the subgroup analysis, increasing CRP (by 1 mg/l) was associated with poor outcome (ORadjusted 1.01, 95% CI 1.01–1.02) and mortality (ORadjusted 1.01, 95% CI 1.01–1.02) but not with sICH (ORadjusted 1.00, 95% CI 0.99–1.01) (Table 4).

### Discussion

Key results for the association between white blood cell counts (WBC) and outcomes in acute ischemic stroke patients treated with IVT were: (i) Leukocytosis on admission independently predicted poor functional outcome and mortality. This association was even more pronounced in the subgroup of patients with combined leukocytosis and elevated CRP. (ii) Neither leukocytosis nor the combination of leukocytosis and elevated CRP was significantly associated with the occurrence of sICH. (iii) Leukopenia was not associated with any outcome.

Previous studies revealed an association between leukocytosis as well as elevated CRP on admission and more severe strokes and larger infarct volumes [6–9]. In line, patients with leukocytosis in the present study had higher baseline NIHSS than patients with normal WBC (median NIHSS 10 vs 8). This difference was even more pronounced in the subgroup of patients with combined leukocytosis and elevated CRP (median NIHSS 12 vs 8) suggesting that the extent of brain injury might — at least partly — be reflected by inflammatory parameters. Another explanation for the higher stroke severity in patients with elevated inflammatory parameters might be that those patients had significantly longer time intervals between stroke onset and administration than patients with normal WBC (median 166 min vs 140 min). Despite the fact, that our study was not designed to investigate potential causes of treatment delay, these associations stress the importance of investigating outcomes in this patient cohort. Yet, the effect of leukocytosis on outcomes and hemorrhagic complications in IVT-treated stroke patients in previous studies was controversial. One study, including 985 IVT-treated stroke patients, found an association between baseline leukocytosis and poor outcome [10], whereas in another study, including 846 IVT-treated stroke patients, baseline neutrophil count but not leukocytosis independently predicted poor outcome and mortality [11]. A third study found baseline WBC < 8.1 × 10⁹/l to be associated with favorable outcome in IVT-treated stroke patients (n = 657) and suggested further investigation of WBC in larger prospective datasets [22]. Limitation of these studies is the relatively small number of patients with leukocytosis. In the present study, we found an independent association between leukocytosis and poor functional outcome and mortality, which remained stable over the long period of data collection (1995–2018). Interestingly, association with poor functional outcome and mortality was even stronger in patients with leukocytosis and elevated CRP. Additionally, the probability for poor functional outcome and mortality increased with rising WBC and CRP. However, every increase in WBC by 1 × 10⁹/l increased the odds of poor functional outcome by 4% which is likely of minor clinical relevance. While we cannot evaluate the cause of the association between elevated inflammatory parameters and worse clinical outcome, it is likely that elevated inflammatory parameters contribute directly —e.g., via leucocyte clogging [23] — and indirectly — reflecting a co-existing disorder — to outcome after IVT.

Because patients with laboratory signs of systemic inflammation had higher NIHSS at onset and larger stroke volumes [6–9], it would have been likely that hemorrhagic complications after thrombolysis (sICH) occur more often in patients with laboratory signs of systemic inflammation than in those without. Accordingly, experimental research found that leucocytes contribute to vascular damage and disruption of the blood–brain barrier [24, 25]. Furthermore, one previous study revealed an independent association between baseline leukocytosis and occurrence of sICH [10].
and another recent study investigating 510 ischemic stroke patients (196 treated with IVT) suggested an association of high WBC with parenchymal hemorrhage independent of infections [26]. However, in our study, after adjustment for potential confounders, neither leukocytosis nor the combination of leukocytosis and elevated CRP was independently associated with increased rate of sICH. Because increased baseline NIHSS, onset-to-treatment time and glucose levels on admission — all well-established risk factors of sICH — were more often present in patients with leukocytosis, we assume that the unadjusted association of leukocytosis with sICH is mostly due to these confounding parameters. Therefore, it seems unlikely that the association between elevated systemic inflammation parameters and poor outcome and mortality is caused by sICH.

Leukopenia — as defined by hematologic criteria — has not been investigated in IVT-treated stroke patients prior to this study. Numerous causes of leukopenia are likely to be associated with worse outcome (e.g., (viral) infections, (hematotoxic) drugs, autoimmune disorders, radiation, renal failure, malignancies, malnutrition) [27, 28]. Additionally, lymphopenia was shown to independently predict unfavorable outcome in intracerebral hemorrhage [29]. In our study, however, presence of leukemia on admission was rare (1.0%) and did not change the odds for any outcome suggesting that leukopenia is rather a chance finding than a manifestation of an outcome modifying disorder in this patient cohort.

Strengths of our study are the large sample size ($n = 10,813$) which allowed adjusting for multiple confounding variables and thus clarifying the inconsistencies of previous studies. We also included a subgroup analysis with combined leukocytosis and elevated CRP which is a novelty and underlined the effect of systemic inflammation on clinical outcomes. Finally, we were able to assess outcomes in patients with leukopenia.

The present study has limitations apart from general limitations of register-based, retrospective studies: (i) causes of leukocytosis and elevated CRP were unclear and information on disorders that are likely associated with systemic inflammatory response (e.g., infections at admission, malignancies, rheumatologic disorders or certain medication) was not collected and it was not possible to determine whether leukocytosis was a trigger for stroke. However, as patients suffering from chronic infections or cancer are likely to have pre-existing disability, we were at least able to partly address this issue by adjusting for pre-stroke mRS. (ii) There is growing evidence on the strong linkage between ischemia and inflammation/immunity [30, 31], and immunomodulation agents are evaluated for acute stroke therapy and stroke prevention [32, 33]. Yet, the observational design of our study does not allow conclusions on potential therapeutic measures modulating the inflammatory response. (iii) Leukocyte subclasses were not available. Thus, we were not able to examine the previously described association of neutrophils/neutrophil-to-lymphocyte ratio with poor outcome, mortality and sICH [11] in our patient cohort. In addition, the association between leukopenia and outcomes was difficult to interpret as red blood cell and platelet counts were not available.

**Appendix**

See below Table 5 here.

**Supplementary Information** The online version contains supplementary material available at https://doi.org/10.1007/s00415-022-11173-0.

**Funding** Open access funding provided by University of Basel.

**Declarations**

**Conflicts of interest** V.L. Altersberger, G. Sibolt, A. Zietz, A. Schaufelbühl, A. Polymeris, C. Hametner, M. Heyse, G. Biglardi, J. Stolp, T.J. van Velzen, G. Padína, N. Slavova, M. Tainten, K. Valkonen, L. Vandelli, M. Magoni, A. Luft, A. Pezziini, S. Nannoni, S. Räty, and S. Curtze report no disclosures. Lukas S Enz has received funding from the Swiss National Science Foundation (323530_171139). M.R. Heldner reports Scientific Advisory honoraria by Amgen and a grant from the Bangerter foundation, outside the submitted work. A. Zini has received funding for speaker honoraria and consulting fees from Boehringer-Ingelheim and Medtronic, speaker honoraria from Cerenovus, for scientific advisory board from Boehringer-Ingelheim and Stryker. V. Padjen travel or speaker honoraria from Boehringer Ingelheim and Pfizer; honoraria from scientific advisory board from Medtronic. C. Gumbinger is the head of the commission telestroke service of the German Stroke Society (DSG). D. Strambo has received congress travel support from Bristol-Myers Squibb, and research grant from the Swiss Heart Foundation and from the University of Lauzanne. All fees are paid to his institution. C.W. Cereda has received modest honoraria for scientific advisory board from Bayer, Boehringer-Ingelheim and iSchemaview; Research grants from the Swiss Heart Foundation. Susanne Wegener received research funds by the Swiss National Science Foundation, the UZH Clinical research priority program (CRPP) stroke, the Swiss Heart foundation, Boehringer-Ingelheim, a speaker honorarium from Amgen and a consultancy fee from Bayer. Y. Béjot reports personal fees from AstraZeneca, BMS, Pfizer, Medtronic, MSD France, Amgen, Servier, and Boehringer-Ingelheim, outside the submitted work. D.R. Jovanović has received for travel or speak-er honoraria from Bayer, Boehringer Ingelheim, Pfizer, Sanofi and Medtronic. She has served on scientific advisory board for Boehringer Ingelheim. P. Stanarcevic has received travel or speaker honoraria from Boehringer Ingelheim, Pfizer and Sandoz; also, honoraria from scientific advisory board from Medtronic and Boehringer Ingelheim. P. Michel has received has received through his institution research grants from the Swiss National Science Foundation, the Swiss Heart Foundation and the ERISTA program (Pfizer/BMS); and consulting fees from Medtronic. All this support is goes to his institution and is used for stroke education and research. P.A. Ringleb has received modest honoraria for lectures and advisory board from Boehringer-Ingelheim. The University Hospital Heidelberg is sponsor of the ECASS4 trial, examining the role of rtPA in an extended time-window, which
| Name                        | Location                        | Role                        | Contribution                                                                 |
|-----------------------------|---------------------------------|-----------------------------|------------------------------------------------------------------------------|
| Paul Nederkoorn, MD, PhD    | Amsterdam UMC                   | Global Principal Investigator| Co-founder of TRISP designs and conceptualizes studies                        |
|                             |                                 | Site Principal Investigator  | Analyzes and interprets data                                                 |
|                             |                                 |                             | Drafts manuscripts                                                           |
|                             |                                 |                             | Revises manuscripts                                                          |
|                             |                                 |                             | Collects data                                                                |
| Yvo Roos, MD, PhD           | Amsterdam UMC                   | Site Investigator            | Revises manuscripts                                                          |
|                             |                                 |                             | Collects data                                                                |
| Sophie van den Berg, MD     | Amsterdam UMC                   | Site Investigator            | Revises manuscripts                                                          |
|                             |                                 |                             | Collects data                                                                |
| Lotte Stolze                | Amsterdam UMC                   | Site Investigator            | Analyzes and interprets data                                                 |
|                             |                                 |                             | Drafts manuscripts                                                           |
|                             |                                 |                             | Revises manuscripts                                                          |
|                             |                                 |                             | Collects data                                                                |
| Thomas Zonneveld, MD        | Amsterdam UMC                   | Site Investigator            | Analyzes and interprets data                                                 |
|                             |                                 |                             | Drafts manuscripts                                                           |
|                             |                                 |                             | Revises manuscripts                                                          |
|                             |                                 |                             | Collects data                                                                |
| Leon Rinkel, MD             | Amsterdam UMC                   | Site Investigator            | Revises manuscripts                                                          |
|                             |                                 |                             | Collects data                                                                |
| Stefan Engelter, MD         | University Hospital, Basel      | Global Principal Investigator| Co-founder of TRISP designs and conceptualizes studies                        |
|                             |                                 |                             | Analyzes and interprets data                                                 |
|                             |                                 |                             | Drafts manuscripts                                                           |
|                             |                                 |                             | Revises manuscripts                                                          |
|                             |                                 |                             | Collects data                                                                |
| Henrik Gensicke, MD         | University Hospital, Basel      | Site Principal Investigator  | Leads and coordinates communication among sites                              |
|                             |                                 | Global Network Coordinator   | Designs and conceptualizes studies                                           |
|                             |                                 |                             | Analyzes and interprets data                                                 |
|                             |                                 |                             | Drafts manuscripts                                                           |
|                             |                                 |                             | Revises manuscripts                                                          |
|                             |                                 |                             | Collects data                                                                |
| Valerian Altersberger, MD   | University Hospital, Basel      | Site Investigator            | Designs and conceptualizes studies                                           |
|                             |                                 |                             | Analyzes and interprets data                                                 |
|                             |                                 |                             | Drafts manuscripts                                                           |
|                             |                                 |                             | Revises manuscripts                                                          |
|                             |                                 |                             | Collects data                                                                |
| Lukas Simon Enz, MD, PhD    | University Hospital, Basel      | Site Investigator            | Analyzes and interprets data                                                 |
|                             |                                 |                             | Revises manuscripts                                                          |
|                             |                                 |                             | Collects data                                                                |
| Leo Bonati, MD              | University Hospital, Basel      | Site Investigator            | Revises manuscripts                                                          |
|                             |                                 |                             | Collects data                                                                |
| Gian Marco De Marchis, MD, MSc| University Hospital, Basel   | Site Investigator            | Revises manuscripts                                                          |
|                             |                                 |                             | Collects data                                                                |
| Philippe Lyrer, MD          | University Hospital, Basel      | Site Investigator            | Revises manuscripts                                                          |
|                             |                                 |                             | Collects data                                                                |
| Alexandros Polymeris, MD    | University Hospital, Basel      | Site Investigator            | Revises manuscripts                                                          |
|                             |                                 |                             | Collects data                                                                |
| Marios Psychogios, MD       | University Hospital, Basel      | Site Investigator            | Revises manuscripts                                                          |
|                             |                                 |                             | Collects data                                                                |
| Alex Brehm, MD              | University Hospital, Basel      | Site Investigator            | Revises manuscripts                                                          |
|                             |                                 |                             | Collects data                                                                |
| Visnja Padjen, MD, PhD      | Clinical Centre of Serbia, Belgrade| Site Principal Investigator | Designs and conceptualizes studies                                           |
|                             |                                 |                             | Revises manuscripts                                                          |
|                             |                                 |                             | Collects data                                                                |
| Dejana Jovanovic, MD, PhD   | Clinical Centre of Serbia, Belgrade| Site Investigator          | Collects data                                                                |
|                             |                                 |                             | Revises manuscripts                                                          |
| Name                        | Location                              | Role                          | Contribution                                                                 |
|-----------------------------|---------------------------------------|-------------------------------|----------------------------------------------------------------------------|
| Ivana Berisavac, MD, PhD    | Clinical Centre of Serbia, Belgrade   | Site Investigator             | Collects data, Revises manuscripts                                           |
| Marko Ercegovac, MD, PhD    | Clinical Centre of Serbia, Belgrade   | Site Investigator             | Revises manuscripts                                                          |
| Predrag Stanarcevic, MD     | Clinical Centre of Serbia, Belgrade   | Site Investigator             | Collects data, Revises manuscripts                                           |
| Maja Budimkic, MD, PhD      | Clinical Centre of Serbia, Belgrade   | Site Investigator             | Collects data, Revises manuscripts                                           |
| Ljiljana Bumbasirevic, MD, PhD | Clinical Centre of Serbia, Belgrade | Site Investigator             | Collects data, Revises manuscripts                                           |
| Christian Nolte, MD         | University Hospital Charite, Berlin    | Site Principal Investigator   | Designs and conceptualizes studies, Analyzes and interprets data, Drafts manuscripts, Revises manuscripts, Collects data |
| Hebun Erdur, MD             | University Hospital Charite, Berlin    | Site Investigator             | Designs and conceptualizes studies, Analyzes and interprets data, Drafts manuscripts, Revises manuscripts, Collects data |
| Jan Scheitz, MD             | University Hospital Charite, Berlin    | Site Investigator             | Designs and conceptualizes studies, Analyzes and interprets data, Drafts manuscripts, Revises manuscripts, Collects data |
| Marcel Arnold, MD           | University Hospital, Bern             | Site Principal Investigator   | Designs and conceptualizes studies, Analyzes and interprets data, Drafts manuscripts, Revises manuscripts, Collects data |
| Mirjam Heldner, MD, MSc     | University Hospital, Bern             | Site Principal Investigator   | Designs and conceptualizes studies, Analyzes and interprets data, Drafts manuscripts, Revises manuscripts, Collects data |
| Urs Fischer, MD, MSc        | University Hospital, Bern             | Site Investigator             | Interprets data, Drafts manuscripts, Revises manuscripts, Collects data      |
| Simon Jung, MD              | University Hospital, Bern             | Site Investigator             | Analyzes and interprets data, Drafts manuscripts, Revises manuscripts, Collects data |
| Roland Wiest, MD            | University Hospital, Bern             | Site Investigator             | Interprets data, Drafts manuscripts, Revises manuscripts, Collects data      |
| Andrea Zini, MD             | IRCCS Istituto delle Scienze Neurologiche, Bologna | Site Principal Investigator | Analyzes and interprets data, Drafts manuscripts, Revises manuscripts, Collects data |
| Mauro Gentile, MD           | IRCCS Istituto delle Scienze Neurologiche, Bologna | Site Investigator | Revises manuscripts, Collects data                                             |
| Andreas Kastrup             | Bremen                                | Site Principal Investigator   | Interprets data, Collects data, Revises manuscripts                          |
| Panagiotis Papanagiotou     | Bremen                                | Site Investigator             | Interprets data, Collects data, Revises manuscripts                          |
| Alessandro Pezzini, MD      | ASST Spedali Civili, Brescia          | Site Principal Investigator   | Collects data, Revises manuscripts                                           |
Table 5 (continued)

| Name                        | Location                  | Role                        | Contribution                                                                 |
|-----------------------------|---------------------------|-----------------------------|-----------------------------------------------------------------------------|
| Mauro Magoni, MD            | ASST Spedali Civili, Brescia | Site Investigator           | Collects data<br>Revises manuscripts                                        |
| Alessandro Padovani, MD, PhD| ASST Spedali Civili, Brescia | Site Investigator           | Collects data<br>Revises manuscripts                                        |
| Yannick Béjot, MD, PhD      | University Hospital, Dijon | Site Principal Investigator  | Designs and conceptualizes studies<br>Analyzes and interprets data<br>Drafts manuscripts<br>Revises manuscripts<br>Collects data |
| Maurice Giroud, MD, PhD     | University Hospital, Dijon | Site Investigator           | Collects data                                                              |
| Guy-Victor Osseby, MD       | University Hospital, Dijon | Site Investigator           | Collects data                                                              |
| Marie Hervieu-Bègue, MD     | University Hospital, Dijon | Site Investigator           | Collects data                                                              |
| Christelle Blanc-Labarre, MD| University Hospital, Dijon | Site Investigator           | Collects data                                                              |
| Benoit Delpont, MD          | University Hospital, Dijon | Site Investigator           | Collects data                                                              |
| Annika Nordanstig           | University Hospital, Gothenburg | Site Investigator     | Analyzes and interprets data<br>Drafts manuscripts<br>Revises manuscripts<br>Collects data |
| Jan-Erik Karlsson, MD, PhD  | University Hospital, Gothenburg | Site Investigator     | Revises manuscripts<br>Collects data                                        |
| Camilla Karlsson, MD        | University Hospital, Gothenburg | Site Investigator     | Analyzes and interprets data<br>Revises manuscripts<br>Collects data         |
| Alexandros Rentzos, MD, PhD | University Hospital, Gothenburg | Site Investigator     | Revises manuscripts<br>Collects data                                        |
| Katarina Jood, MD, PhD      | University Hospital, Gothenburg | Site Investigator     | Revises manuscripts<br>Collects data                                        |
| Turgut Tatlisumak, MD, PhD  | University Hospital, Gothenburg | Site Principal Investigator | Designs and conceptualizes studies<br>Analyzes and interprets data<br>Drafts manuscripts<br>Revises manuscripts<br>Collects data |
| Jan Liman, MD               | University medical center, Göttingen | Site Principal Investigator | Revises manuscripts<br>Collects data                                        |
| Peter Ringleb, MD           | University Hospital, Heidelberg | Site Principal Investigator | Designs and conceptualizes studies<br>Analyzes and interprets data<br>Drafts manuscripts<br>Revises manuscripts<br>Collects data |
| Christian Hametner, MD, MSc | University Hospital, Heidelberg | Site Investigator | Designs and conceptualizes studies<br>Analyzes and interprets data<br>Drafts manuscripts<br>Revises manuscripts<br>Collects data |
| Timolaos Rizos, MD          | University Hospital, Heidelberg<br>Alfried Krupp Hospital, Essen | Site Investigator | Designs and conceptualizes studies<br>Revises manuscripts<br>Collects data |
| Mona Laible, MD             | University Hospital, Heidelberg | Site Investigator | Designs and conceptualizes studies<br>Revises manuscripts<br>Collects data |
| Anne Berberich, MD          | University Hospital, Heidelberg | Site Investigator | Revises manuscripts<br>Collects data                                        |
| Christoph Gumbinger, MD     | University Hospital, Heidelberg | Site Investigator | Revises manuscripts<br>Collects data                                        |
| Name                          | Location                                | Role                        | Contribution                                                                                                                                 |
|-------------------------------|-----------------------------------------|-----------------------------|----------------------------------------------------------------------------------------------------------------------------------------------|
| Sami Curtze, PhD, MD, MSc     | University Hospital, Helsinki           | Site Principal Investigator | Designs and conceptualizes studies Analyzes and interprets data Drafts manuscripts Revises manuscripts Collects data                        |
| Nicolas Martinez-Majander, MD| University Hospital, Helsinki           | Site Investigator           | Designs and conceptualizes studies Analyzes and interprets data Drafts manuscripts Revises manuscripts Collects data                        |
| Jukka Putaala, PhD, MD, MSc   | University Hospital, Helsinki           | Site Investigator           | Designs and conceptualizes studies Analyzes and interprets data Drafts manuscripts Revises manuscripts Collects data                        |
| Silja Räty, MD, MSc           | University Hospital, Helsinki           | Site Investigator           | Designs and conceptualizes studies Analyzes and interprets data Drafts manuscripts Revises manuscripts Collects data                        |
| Gerli Sibolt, MD, MSc         | University Hospital, Helsinki           | Site Investigator           | Designs and conceptualizes studies Analyzes and interprets data Drafts manuscripts Revises manuscripts Collects data                        |
| Daniel Strbian, PhD, MD, MSc  | University Hospital, Helsinki           | Site Investigator           | Designs and conceptualizes studies Analyzes and interprets data Drafts manuscripts Revises manuscripts Collects data                        |
| Marjaana Tiainen, PhD, MD, MSc| University Hospital, Helsinki           | Site Investigator           | Designs and conceptualizes studies Analyzes and interprets data Drafts manuscripts Revises manuscripts Collects data                        |
| Kati Valkonen, MD             | University Hospital, Helsinki           | Site Investigator           | Revises manuscripts Collects data                                                                                                           |
| Ronen Leker, MD               | Hadassah-Hebrew University Medical Center, Jerusalem | Site Principal Investigator | Designs and conceptualizes studies Analyzes and interprets data Drafts manuscripts Revises manuscripts Collects data                        |
| Asaf Honig, MD                | Hadassah-Hebrew University Medical Center, Jerusalem | Site Investigator           | Analyzes and interprets data Revises manuscripts Collects data                                                                            |
| Andrei Filioglo, MD           | Hadassah-Hebrew University Medical Center, Jerusalem | Site Investigator           | Analyzes and interprets data Revises manuscripts Collects data                                                                            |
| Jose E. Cohen, MD             | Hadassah-Hebrew University Medical Center, Jerusalem | Site Investigator           | Analyzes and interprets data Revises manuscripts Collects data                                                                            |
| Georges Ntaios, MD, PhD       | University of Thessaly, Larissa         | Site Principal Investigator | Analyzes and interprets data Revises manuscripts Collects data                                                                            |
| Patrik Michel, MD             | University Hospital, Lausanne           | Site Principal Investigator | Analyzes and interprets data Revises manuscripts Collects data                                                                            |
| Name                             | Location                                          | Role                     | Contribution                                                                 |
|----------------------------------|---------------------------------------------------|--------------------------|------------------------------------------------------------------------------|
| Stefania Nannoni, MD             | University Hospital, Lausanne                     | Site Investigator        | Collects data, Revises manuscripts                                           |
| Davide Strambo, MD               | University Hospital, Lausanne                     | Site Investigator        | Collects data, Revises manuscripts                                           |
| Gaia Sirimaro, MD, PhD           | University Hospital, Lausanne                     | Site Investigator        | Collects data, Revises manuscripts                                           |
| Marie Bodenant, MD               | University Hospital, Lille                        | Site Investigator        | Collects data, Revises manuscripts                                           |
| Charlotte Cordonnier, MD, PhD    | University Hospital, Lille                        | Site Principal Investigator | Collects data, Revises manuscripts                                           |
| Nelly Dequatre-Ponchelle, MD     | University Hospital, Lille                        | Site Investigator        | Collects data, Revises manuscripts                                           |
| Hilde Hénon, MD, PhD             | University Hospital, Lille                        | Site Investigator        | Collects data, Revises manuscripts                                           |
| Yaohua Chen, MD                  | University Hospital, Lille                        | Site Investigator        | Collects data, Revises manuscripts                                           |
| Solène Moulin, MD, MSc           | University Hospital, Lille                        | Site Investigator        | Collects data, Revises manuscripts                                           |
| Carlo Cereda, MD                 | Neurocenter of Southern Switzerland, Lugano       | Site Principal Investigator | Designs and conceptualizes studies, Analyzes and interprets data, Drafts manuscripts, Revises manuscripts, Collects data |
| Giovanni Bianco, MD              | Neurocenter of Southern Switzerland, Lugano       | Site Investigator        | Analyzes and interprets data, Collects data, Revises manuscripts             |
| Guido Bigliardi, MD              | University Hospital, Modena                       | Site Principal Investigator | Collects data, Revises manuscripts                                           |
| Laura Vandelli, MD               | University Hospital, Modena                       | Site Investigator        | Collects data, Revises manuscripts                                           |
| Maria Dell’Acqua, MD             | University Hospital, Modena                       | Site Investigator        | Collects data, Revises manuscripts                                           |
| Francesca Rosafio, MD            | University Hospital, Modena                       | Site Investigator        | Collects data, Revises manuscripts                                           |
| Livio Picchetto, MD              | University Hospital, Modena                       | Site Investigator        | Collects data, Revises manuscripts                                           |
| Stefania Maffei, MD, PhD         | University Hospital, Modena                       | Site Investigator        | Collects data, Revises manuscripts                                           |
| Stefano Meletti, MD              | University Hospital, Modena                       | Site Investigator        | Collects data, Revises manuscripts                                           |
| Valentina Fioravanti, MD         | University Hospital, Modena                       | Site Investigator        | Collects data, Revises manuscripts                                           |
| Giuseppe Borzi, MD               | University Hospital, Modena                       | Site Investigator        | Collects data, Revises manuscripts                                           |
| Riccardo Ricceri, MD             | University Hospital, Modena                       | Site Investigator        | Collects data, Revises manuscripts                                           |
| Lars Kellert, MD                 | Ludwig Maximilians University, Munich             | Site Principal Investigator | Designs and conceptualizes studies, Analyzes and interprets data, Drafts manuscripts, Revises manuscripts, Collects data |
| Katharina Feil, MD               | Ludwig Maximilians University, Munich             | Site Investigator        | Collects data, Revises manuscripts                                           |

 Springer
Table 5 (continued)

| Name                  | Location                                      | Role                        | Contribution                                                                 |
|-----------------------|-----------------------------------------------|-----------------------------|-----------------------------------------------------------------------------|
| Clemens Küpper, MD    | Ludwig Maximilians University, Munich         | Site Investigator           | Collects data; Analyzes and interprets data; Drafts manuscripts             |
| Johanna Heinrich, MD  | Ludwig Maximilians University, Munich         | Site Investigator           | Collects data; Analyzes and interprets data; Drafts manuscripts             |
| Marialuisa Zedde, MD  | Azienda USL-IRCCS, Reggio Emilia              | Site Principal Investigator | Collects data; Analyzes and interprets data; Revises manuscripts           |
| Jean-Louis Mas, MD    | Centre Hospitalier Sainte-Anne, Paris         | Site Investigator           | Collects data; Revises manuscripts                                           |
| Catherine Oppenheim, MD, PhD | Centre Hospitalier Sainte-Anne, Paris      | Site Investigator           | Collects data; Revises manuscripts                                           |
| Pierre Seners, MD, MSc| Centre Hospitalier Sainte-Anne, Paris         | Site Investigator           | Collects data; Revises manuscripts                                           |
| Guillaume Turc, MD, PhD| Centre Hospitalier Sainte-Anne, Paris         | Site Principal Investigator | Collects data; Revises manuscripts                                           |
| Bruno Gonçalves, MD   | Centre Hospitalier Sainte-Anne, Paris         | Site Principal Investigator | Collects data; Revises manuscripts                                           |
| Georg Kaegi, MD       | Kantonsspital St. Gallen                      | Site Principal Investigator | Analyzes and interprets data; Drafts manuscripts; Revises manuscripts       |
| Susanne Wegener, MD   | University Hospital, Zurich                   | Site Principal Investigator | Designs and conceptualizes studies; Analyzes and interprets data; Drafts manuscripts; Revises manuscripts; Collects data |
| Laura Westphal, MD    | University Hospital, Zurich                   | Site Investigator           | Analyzes and interprets data; Drafts manuscripts; Collects data             |
| Philipp Baumgartner, MD| University Hospital, Zurich                   | Site Investigator           | Analyzes and interprets data; Revises manuscripts                            |
| Andreas Luft, MD      | University Hospital, Zurich                   | Site Investigator           | Analyzes and interprets data; Revises manuscripts                            |

is financed by Boehringer-Ingelheim. M. Arnold received Speaker honoraria from Bayer, Boehringer Ingelheim, and Covidien; Scientific advisory board honoraria from Amgen, Bayer, Boehringer Ingelheim, BMS, Pfizer, Covidien, Daichi Sanyko and Nestlé Health Science. Research grants from the Swiss Heart Foundation and the Swiss National Science Foundation. P.J. Nederkoorn has received funding from the Dutch heart foundation for acute stroke intervention trials in the Collaboration for New Trials in Stroke (CONTRAST) consortium. S.T. Engelster has received funding for travel or speaker honoraria from Bayer Boehringer-Ingelheim, and Daiichi-Sanyko. He has served on scientific advisory boards for Bayer, Boehringer-Ingelheim, BMS/ Pfizer, MindMaze and on the editorial board of Stroke. He has received an educational grant from Pfizer and research support from the Science Funds (Wissenschaftsfonds) of the University Hospital Basel, the University Basel, the Swiss Heart Foundation and the Swiss National Science Foundation. H. Gensicke has received research support from the Swiss National Science Foundation, advisory board honoraria from Daichi Sanyko and funding for travel from BMS/Pfizer.

**Ethical standards** The study was approved by the ethics committee in Basel, Switzerland and written informed consent was waived. The requirement for additional local ethical approval differed between participating centers and was obtained if required.

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creativecommons.org/licenses/by/4.0/](http://creativecommons.org/licenses/by/4.0/).
Patrik Michel4 · Peter A. Ringleb3 · Sami Curtze2 · Stefan T. Engelter1,17 · Henrik Gensicke1,17 · for the Thrombolysis in Stroke Patients (TRISP) collaborators

1 Stroke Center and Department of Neurology, University Hospital Basel and University of Basel, Petersgraben 4, CH–4031 Basel, Switzerland
2 Neurology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland
3 Department of Neurology, University Hospital Heidelberg, Heidelberg, Germany
4 Department of Neurology, Service of Clinical Neurosciences, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland
5 Department of Neurology, Inselspital, Bern University Hospital and University of Bern, Bern, Switzerland
6 Department of Neurology, Amsterdam UMC, Location AMC, University of Amsterdam, Amsterdam, The Netherlands
7 Neurology Clinic, Clinical Centre of Serbia, Faculty of Medicine, University of Belgrade, Belgrade, Serbia
8 Department of Neurology and Stroke Center, IRCCS Istituto Delle Scienze Neurologiche Di Bologna, Maggiore Hospital, Bologna, Italy
9 Department of Clinical and Experimental Sciences, Neurology Clinic, University of Brescia, Neurology Unit, ASST Spedali Civili, Brescia, Italy
10 Department of Neurology, University Hospital Zurich and University of Zurich, Zurich, Switzerland
11 Stroke Center and Department of Neurology, Neurocenter of Southern Switzerland, Lugano, Switzerland
12 Department of Internal Medicine, School of Medicine, Larissa University Hospital, University of Thessaly, Larissa, Greece
13 Department of Diagnostic and Interventional Neuroradiology and Department of Interventional, Pediatric and Diagnostic Radiology, Inselspital, Bern University Hospital and University of Bern, Bern, Switzerland
14 Stroke Unit, Department of Neuroscience, Ospedale Civile S. Agostino-Estense, Modena University Hospital, Modena, Italy
15 Vascular Neurology – Stroke Unit, Spedali Civili Hospital, ASST Spedali Civili, Brescia, Italy
16 Department of Neurology, University Hospital Dijon, Dijon, France
17 Neurology and Neurorehabilitation, Center for Medicine of Aging and Rehabilitation, University of Basel and University, Felix Platter Hospital, Basel, Switzerland